Holen Sie sich die Stockscreener-App
3.955
2.10%
-0.085
Handel nachbörslich:
3.94
-0.015
-0.38%
Schlusskurs vom Vortag:
$4.04
Offen:
$4
24-Stunden-Volumen:
226.50K
Relative Volume:
0.80
Marktkapitalisierung:
$161.86M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$109.16M
KGV:
1.5309
EPS:
2.5835
Netto-Cashflow:
$-9.11M
1W Leistung:
-13.46%
1M Leistung:
+2.20%
6M Leistung:
+16.67%
1J Leistung:
+85.25%
1-Tages-Spanne:
$3.93
$4.05
1-Wochen-Bereich:
$3.93
$4.62
52-Wochen-Spanne:
$1.975
$5.19
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.955 | 165.34M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects - ad-hoc-news.de
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - AOL.com
Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr - ad-hoc-news.de
Price to earnings forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals stock holds its ground. Investors await the next company update. - ad-hoc-news.de
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma - GuruFocus
Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K - TradingView
Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise - Stock Titan
ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares - Stock Titan
Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings - TradingView
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com - Investing.com South Africa
137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144 - Stock Titan
Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026 - Stock Titan
Oramed Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions - TipRanks
Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Value Benchmark - marketscreener.com
BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 3000E Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Value-Defensive Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2500 Value Benchmark - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Defensive Index - marketscreener.com
Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1) - TradingView
Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1) - TradingView
These healthcare stocks are combining strong gains with reasonable prices - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Oramed Releases Letter to Shareholders, Highlighting Russell 200 - GuruFocus
Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP) - TradingView
Oramed's Pivot Pays Off: From Pharma Hopeful to Investment Powerhouse - BriefGlance
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORMP SEC FilingsOramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Daily Brief United States: Tesla , Adobe Systems, Nine Energy Service , Oramed Pharmaceuticals , Olin Corp, Earth Science Tech, Kardigan, Generac Holdings, General Motors, Nucor Corp and more - Smartkarma
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026 - GuruFocus
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oramed Pharmaceuticals Inc - TradingKey
Oramed Pharmaceuticals to join Russell 2000, 3000 indexes - Investing.com
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PR Newswire
Oramed (NNDM holder) lifts Nano Dimension stake to 7.2% and opposes proposed deal - Stock Titan
June 2026 Penny Stocks To Watch For Potential Growth - Yahoo Finance
ORMP Q4 2025 Earnings: Surprise Profit as EPS Exceeds Zero EstimateEarnings Momentum Score - dars.gov.et
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oramed Pharmaceuticals Inc-Aktie (ORMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO |
Jul 01 '26 |
Sale |
4.46 |
137,000 |
611,431 |
1,023,384 |
| Gabay Avraham | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.51 |
73,360 |
330,744 |
671,785 |
5.60%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):